Catalyst Pharmaceuticals Inc. (CPRX)
Strength Seen in Catalyst (CPRX): Can Its 6.7% Jump Turn into More Strength?
Catalyst (CPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
CPRX or UTHR: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and United Therapeutics (UTHR). But which of these two stocks is more attractive to value investors?
Does Catalyst (CPRX) Have the Potential to Rally 28.87% as Wall Street Analysts Expect?
The mean of analysts' price targets for Catalyst (CPRX) points to a 28.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Recent Price Trend in Catalyst (CPRX) is Your Friend, Here's Why
Catalyst (CPRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
CPRX or UTHR: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and United Therapeutics (UTHR). But which of these two stocks offers value investors a better bang for their buck right now?
Wall Street Analysts Predict a 45.3% Upside in Catalyst (CPRX): Here's What You Should Know
The mean of analysts' price targets for Catalyst (CPRX) points to a 45.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Catalyst (CPRX) Down 2.5% Since Last Earnings Report: Can It Rebound?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
CPRX vs. UTHR: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and United Therapeutics (UTHR). But which of these two companies is the best option for those looking for undervalued stocks?
Catalyst Pharmaceuticals Touts Firdapse Growth, Agamree Traction as Fycompa Faces Generics
Catalyst Pharmaceuticals (NASDAQ: CPRX) highlighted continued growth in its rare disease portfolio and outlined efforts to expand patient identification and penetration for its lead product during a recent discussion with Barclays life sciences analyst Glen Santangelo. Chief Executive Officer Rich Daly also reviewed early commercial progress for Agamree in Duchenne muscular dystrophy (DMD), provided an update
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
How Much Upside is Left in Catalyst (CPRX)? Wall Street Analysts Think 43.34%
The consensus price target hints at a 43.3% upside potential for Catalyst (CPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
